BRIEF-Valeant CEO says double digit organic growth will continue

Wed Dec 16, 2015 8:40am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Dec 16 (Reuters) - Valeant Pharmaceuticals International Inc

* Valeant CEO says will not budget research and development as a certain percentage of sales, but will review it regularly

* Valeant CEO says Addyi sales expected at $100 million to $150 million in 2016

* Valeant says anticipates $250 million loss in revenue in q4 due to Philidor situation

* Valeant says prescriptions dropped 20 percent in the fourth quarter as it lost all Philidor covered scripts

* Valeant CEO says double digit organic growth will continue in the years after 2016

* Valeant CEO says employee retention plan has worked and has only lost two sales representatives in the dermatology business

* Valeant says canceled all price increases during the fourth quarter

* Valeant says employee retention bonuses targeted at $75 million in 2016 (Reporting By Caroline Humer)